Ira B Dicker

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated
    Jeffrey T Billheimer
    Department of Chemical Enzymology, Bristol-Myers Squibb Pharma Company, Wilmington, DE 19880-0400, USA
    Blood 99:3540-6. 2002
  2. ncbi Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors
    Ira B Dicker
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    J Biol Chem 282:31186-96. 2007
  3. ncbi Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors
    Ira B Dicker
    Department of Virology, Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    J Biol Chem 283:23599-609. 2008
  4. ncbi The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors
    David R Langley
    Department of Computer Assisted Drug Design, Bristol Myers Squibb Research and Development, Wallingford, Connecticut 06492, USA
    Biochemistry 47:13481-8. 2008
  5. ncbi Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
    Tao Wang
    Departments of Chemistry, Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, USA
    J Med Chem 52:7778-87. 2009
  6. ncbi Homogenous assays for Escherichia coli DnaB-stimulated DnaG primase and DnaB helicase and their use in screening for chemical inhibitors
    Yi Zhang
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, Wilmington, DE 19880, USA
    Anal Biochem 304:174-9. 2002

Collaborators

Detail Information

Publications6

  1. ncbi Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated
    Jeffrey T Billheimer
    Department of Chemical Enzymology, Bristol-Myers Squibb Pharma Company, Wilmington, DE 19880-0400, USA
    Blood 99:3540-6. 2002
    ..Screening patients for pre-existing or increasing DDAB titer during treatment with GP IIb/IIIa antagonists may reduce the incidence of drug-induced thrombocytopenia...
  2. ncbi Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors
    Ira B Dicker
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    J Biol Chem 282:31186-96. 2007
    ..4) Gln(148) interacts with G(2), T(1), and C(-1) at the 5' end of the viral LTR, with these four determinants playing important and overlapping roles in assembly, strand transfer catalysis and high affinity inhibitor binding...
  3. ncbi Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors
    Ira B Dicker
    Department of Virology, Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    J Biol Chem 283:23599-609. 2008
    ..Finally, except for T66I, variant viruses harboring the resistance-inducing substitutions were defective for viral integration...
  4. ncbi The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors
    David R Langley
    Department of Computer Assisted Drug Design, Bristol Myers Squibb Research and Development, Wallingford, Connecticut 06492, USA
    Biochemistry 47:13481-8. 2008
    ..These findings further our understanding of the details of the inhibitor binding site of specific strand transfer inhibitors...
  5. ncbi Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
    Tao Wang
    Departments of Chemistry, Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, USA
    J Med Chem 52:7778-87. 2009
    ..In a preliminary clinical study, 4 administered as monotherapy for 8 days, reduced viremia in HIV-1-infected subjects, providing proof of concept for this mechanistic class...
  6. ncbi Homogenous assays for Escherichia coli DnaB-stimulated DnaG primase and DnaB helicase and their use in screening for chemical inhibitors
    Yi Zhang
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, Wilmington, DE 19880, USA
    Anal Biochem 304:174-9. 2002
    ..By this approach, specific primase inhibitors could be identified...